TP53 and non-small cell lung carcinoma: Since mutant p53 overexpression was already identified as an important sensitizer for AF in (isogenic) NSCLC and PDAC cells [14], we investigated the cytotoxic effect of AF and olaparib monotherapy in a NSCLC p53 knock-in and knock-out cell panel.